AR071309A1 - Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten - Google Patents

Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten

Info

Publication number
AR071309A1
AR071309A1 ARP090101264A ARP090101264A AR071309A1 AR 071309 A1 AR071309 A1 AR 071309A1 AR P090101264 A ARP090101264 A AR P090101264A AR P090101264 A ARP090101264 A AR P090101264A AR 071309 A1 AR071309 A1 AR 071309A1
Authority
AR
Argentina
Prior art keywords
humanized
antibody
equipment
methods
combination
Prior art date
Application number
ARP090101264A
Other languages
English (en)
Inventor
Yunqing Li
Roger Abounader
Original Assignee
Univ Virginia
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Galaxy Biotech Llc filed Critical Univ Virginia
Publication of AR071309A1 publication Critical patent/AR071309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Para tratamiento de cáncer se administra al paciente un inhibidor del Factor de Crecimiento de Hepatocito y un agonista de PTEN, proporcionándose un equipo comprendido por un anticuerpo L2G7 humanizado y un agonista PTEN seleccionado del grupo que consiste de rapamicinas, sirolimus y tensirolimus. Reivindicacion 12: El método de la reivindicacion 1, caracterizado porque el cáncer es glioma.
ARP090101264A 2008-04-11 2009-04-08 Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten AR071309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4444608P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
AR071309A1 true AR071309A1 (es) 2010-06-09

Family

ID=41152336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101264A AR071309A1 (es) 2008-04-11 2009-04-08 Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten

Country Status (7)

Country Link
US (1) US20110189169A1 (es)
AR (1) AR071309A1 (es)
CL (1) CL2009000844A1 (es)
PE (1) PE20091714A1 (es)
TW (1) TW200948380A (es)
UY (1) UY31756A1 (es)
WO (1) WO2009126842A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20140234328A1 (en) * 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR TREATING CANCER BY MODULATING AN IMMUNE REACTION AGAINST CANCER
CN111479571A (zh) 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
WO2020018904A1 (en) 2018-07-19 2020-01-23 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
WO2021028081A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
CA3167367A1 (en) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Mirna-193a for promoting immunogenic cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
BRPI0509854A (pt) * 2004-04-14 2007-10-23 Wyeth Corp composto, métodos para a preparação regio-especìfica de um 42-éster de rapamicina ou 42-éster de prolina-rapamicina e para a preparação de um 42-éster de prolina-rapamicina, composição, e, produto
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
US20070036797A1 (en) * 2005-06-02 2007-02-15 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
NZ578329A (en) * 2006-12-13 2012-05-25 Schering Corp Igf1r inhibitors for treating cancer

Also Published As

Publication number Publication date
UY31756A1 (es) 2009-09-30
CL2009000844A1 (es) 2009-06-12
WO2009126842A1 (en) 2009-10-15
TW200948380A (en) 2009-12-01
PE20091714A1 (es) 2009-11-15
US20110189169A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
AR071309A1 (es) Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
MX345467B (es) Metodo para inhibicion de actividad desubiquitinante.
AR083205A1 (es) Metodo para tratar el crecimiento celular anomalo
MA32588B1 (fr) Derives azotes de la pancratistatine
CL2012002858A1 (es) Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras.
EA201270315A1 (ru) Новые формы полициклического соединения
ECSP10010249A (es) Tratamiento de cardiopatías usando -bloqueantes

Legal Events

Date Code Title Description
FB Suspension of granting procedure